New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
08:15 EDTARRY, CGIX, EXEL, GILD, MNK, QSII, AHS, SGENUBS to hold a conference
2014 Global Healthcare Conference to be held in New York on May 19-21 with webcasted company presentations to begin on May 20 at 8 am; not all company presentations may be webcasted. Webcast Link
News For ARRY;CGIX;EXEL;GILD;MNK;QSII;AHS;SGEN From The Last 14 Days
Check below for free stories on ARRY;CGIX;EXEL;GILD;MNK;QSII;AHS;SGEN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 15, 2014
06:12 EDTGILDGilead announced favorable ruling in arbitration against Roche
Gilead (GILD) announced that an arbitration panel determined that Roche (RHHBY) failed to establish any of their claims and ruled in favor of Gilead. As a result, Roche is not entitled to any damages or other relief. In March 2013, Roche initiated an arbitration against Gilead and Pharmasset, predecessor to Gilead Pharmasset, regarding a 2004 collaboration agreement between Roche and Pharmasset. In the arbitration demand, Roche asserted that it had an exclusive license to sofosbuvir pursuant to the collaboration agreement because sofosbuvir, a prodrug of a uridine monophosphate analog, is allegedly a prodrug of PSI-6130, a cytidine analog. Roche further claimed that, because it had exclusive rights to sofosbuvir, it also had an exclusive license to a patent covering sofosbuvir, and that we infringed that patent by selling and offering for sale products containing sofosbuvir.
August 14, 2014
17:20 EDTMNKRowan Companies to replace Mallinckrodt in S&P 400 as of 8/18 close
Subscribe for More Information
17:18 EDTMNKMallinckrodt to replace Rowan Companies in S&P 500 as of 8/18 close
17:16 EDTMNKPaulson & Co gives quarterly update on stakes
Subscribe for More Information
16:35 EDTMNKMallinckrodt completes acquisition of Questcor Pharmaceuticals
Subscribe for More Information
16:01 EDTGILDOptions Update; August 14, 2014
Subscribe for More Information
13:02 EDTMNKMallinckrodt, Questcor holders approve Mallinckrodt's acquisition of Questcor
Subscribe for More Information
12:58 EDTMNKJANA Partners gives quarterly update on stakes
NEW STAKES: Apache (APA), FMC Corp (FMC), Civeo (CVEO), PetSmart (PETM), and Charter Communications (CHTR). INCREASED STAKES: Actavis (ACT), AIG (AIG), Mallinckrodt (MNK), HD Supply (HDS), and American Capital (ACAS). DECREASED STAKES: Liberty (LVNTA), Oil States International (OIS), eBay (EBAY), Liberty Media (LMCA), and Liberty Interactive (LINTA). LIQUIDATED STAKES: Sirius XM (SIRI), Juniper (JNPR), Golar LNG (GLNG), Outerwall (OUTR), and Teva (TEVA).
07:17 EDTCGIXCancer Genetics reports Q2 EPS (50c), consensus (37c)
Subscribe for More Information
August 13, 2014
09:37 EDTGILDActive equity options trading on open
Subscribe for More Information
August 12, 2014
09:01 EDTSGENSeattle Genetics initiates Phase 1 trial of SGN-CD70A
Subscribe for More Information
07:08 EDTARRYArray BioPharma reports Q4 EPS (22c), consensus (23c)
Subscribe for More Information
August 11, 2014
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
07:29 EDTGILDGilead price target raised to $110 from $90 at Argus
Subscribe for More Information
August 8, 2014
08:31 EDTMNKMallinckrodt patent settlement removes key overhang, says Deutsche Bank
Subscribe for More Information
07:45 EDTMNKMallinckrodt price target lowered to $77 from $90 at Leerink
Leerink lowered its price target for Mallinckrodt (MNK) shares to $77 citing a heightened risk profile from the Questcor (QCOR) acquisition and significant earnings concentration in Acthar. The firm says it remains on the sidelines with a Market Perform rating on Mallinckrodt.
07:44 EDTMNKMallinckrodt remains favorite specialty pharmaceutical name, says UBS
UBS said Mallinckrodt (MNK) remains its favorite specialty pharmaceutical name following the company's update on its merger with Questcor (QCOR). The firm sees estimates increasing following the close of the transaction, the divestiture of the Medical Imaging division, and the reinvestment in higher margin assets. UBS has a Buy rating with a $94 price target on Mallinckrodt.
August 7, 2014
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
07:05 EDTMNKMallinckrodt raises FY14 adjusted EPS view to $4.00-$4.30 from $3.30-$3.60
Consensus is $3.82. Raises FY14 net sales view to $2.35B-$2.45B from $2.28B-$2.38B, consensus $2.38B. Cuts FY CapEx view to $115M-$135M from $130M-$150M. Now sees tax rate 22%-25%.
07:03 EDTMNKMallinckrodt reports Q3 adjusted EPS $1.20, consensus 87c
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use